Partnerships
We are continually seeking opportunities with leading biopharmaceutical companies to identify areas of scientific synergy to address unmet medical needs. Through partnerships and collaboration, we can fully leverage Callavid to target and deliver other diverse drugs / hormones / therapies for wider patient benefit.
NIHR
Calla Lily Clinical Care has secured £1 million in funding from the National Institute for Health and Care Research (NIHR) to advance our pioneering Callavid® technology addressing threatened miscarriage. This partnership enables us to begin first-in-person clinical trials and marks a crucial milestone in our mission to transform care for women experiencing threatened miscarriage.
Innovate UK
Calla Lily Clinical Care has been generously supported by Innovate UK—the UK government’s innovation agency—through both its SMART and BioMedical Catalyst funding programmes.
UHCW
Calla Lily Clinical Care is collaborating with University Hospitals Coventry and Warwickshire (UHCW) NHS Trust on a clinical trial of our innovative progesterone delivery device, Callavid®. Led by Professor Siobhan Quenby MBE, a leading expert in miscarriage and preterm birth, the NIHR-funded feasibility study is scheduled for the second half of 2025.
University of Warwick
Our partnership with the University of Warwick establishes a fully funded 4-year MSc/PhD program dedicated to advancing scientific research in vaginal microbiota and women's reproductive health. This collaborative research initiative explores the critical mechanisms by which vaginal microbiota protect against inflammation and pregnancy complications
Queen Mary University of London
Our partnership with Queen Mary University of London advances critical research in women's reproductive health through an innovative PhD studentship focused on developing breakthrough solutions for bacterial vaginosis. Combining our clinical expertise with the university's leading bioengineering capabilities, we are developing a novel microbiome organ-chip model to explore probiotic interventions that could transform treatment approaches for a condition affecting 30% of reproductive-aged women
UCL / UCL Consultants Ltd
We have established a multiyear partnership with UCL Consultants Ltd, working closely with Professor Catherine Tuleu's team to advance drug formulation technology for our Callavid® device.
For more information about partnerships or other business development opportunities, please email us at info@callali.ly or telephone +44 (0) 20 7754 5400